Treatment of palmoplantar psoriasis with oral roflumilast: a case series

Abstract

Palmoplantar psoriasis (PP) is a special area of psoriasis, which can justify systemic treatment. Roflumilast is a targeted inhibitor of phosphodiesterase (IPDE)-4 that has been recently approved by FDA as a cream for the treatment of plaque psoriasis. Also, oral roflumilast has demonstrated efficacy in the treatment of plaque psoriasis in a small randomized clinical trial and single case reports. To the best of our knowledge, we present the first case series of PP treated with oral roflumilast.